Immunocore Management Change

(Oxford, UK and Conshohocken, US, 16 July 2018) Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that Paul Fry will step down from his position of Chief Financial Officer on 26 October 2018. Paul will join Vectura Group PLC, the FTSE listed industry-leading inhaled product formulation, device design and development business, as Chief Financial Officer and Executive Board Member. Immunocore is recruiting a successor and hopes to be able to provide an update in due course. Paul will help support a managed transition.